Aurobindo Pharma Ltd Share Price (AUROPHARMA)

Aurobindo Pharma Sees Increase in Revenue and Profit; ICICI Sets Target Price - 17 Apr, 2024

Aurobindo Pharma sees a rise in revenue and net profit during Q3FY24. ICICI Prudential Mutual Fund acquires 3.60% stake. ICICI Securities sets target price of Rs 1,270 with potential 15% return.

Aurobindo Pharma Reports Q4FY24 Results and Promoter Pledge Increase - 16 Apr, 2024

Aurobindo Pharma reports a growth in consolidated total income and net profit after tax for Q4FY24. Additionally, promoters increased their pledge on company holdings.

Aurobindo Pharma Shares Drop Over 2% After USFDA Observations - 15 Apr, 2024

Aurobindo Pharma's Eugia Sterile unit received three critical observations from the USFDA, citing shortcomings in key areas of plant operations and raising concerns about drug product contamination. The company is expected to address these promptly to maintain regulatory compliance.

Aurobindo Pharma's P/E Ratio May Be Sending Bullish Signals - 10 Apr, 2024

Aurobindo Pharma Limited has a P/E ratio of 23.9x, which is lower than the average for Indian companies. However, further analysis is needed to determine if this reduced P/E is justified.

Aurobindo Pharma Receives Observations from USFDA; Reports Fatal Accident at Subsidiary Facility - 08 Apr, 2024

Aurobindo Pharma received three observations from the USFDA on its Andhra Pradesh subsidiary's new injectable facility. Unfortunately, one person died in an accident at the company's wholly-owned subsidiary in Andhra Pradesh. The stock fell by 1.5%.

Aurobindo Pharma Reports 90.6% YoY Rise in Net Profit - 07 Apr, 2024

Aurobindo Pharma reported a consolidated net profit of Rs 936.2 crore for Q3 FY24, up by 90.6% YoY. The company appointed T. Vijaya Kumar as President - R&D (Specialty Drug Delivery). Aurobindo Pharma had a net capex of $103 million, including $37 million towards its bulk drugs PLI project. Total investment for the PLI project is $230 million while in biosimilar project it is $305 million as of December 31, 2023. Total R&D spend for the quarter is Rs 398 crore.

Aurobindo Pharma Commissions Four Manufacturing Facilities - 06 Apr, 2024

Aurobindo Pharma has commissioned four manufacturing facilities in Andhra Pradesh, including a Penicillin G plant, to boost self-reliance in the pharmaceutical sector. The company's revenue increased by 1.8% from Rs. 7,219 crores during the September quarter to Rs. 7,352 crores in the December quarter. Additionally, net profits rose by 25% from Rs. 752 crores to Rs. 940 crores during the same period.

Aurobindo Pharma Injectable Facility Inspected by US FDA - 05 Apr, 2024

The United States Food and Drug Administration (FDA) inspected Aurobindo Pharma's newly operational injectable facility in Andhra Pradesh and issued three procedural observations. The company stated that it will address the observations within the stipulated timeframe.

Aurobindo Pharma Q3 Net Profit Up by 109% - 03 Apr, 2024

Aurobindo Pharma records a net profit of Rs 623.8 crore for the December quarter, up by 109% YoY. Operating profit margins also improved from 13.79% to 17.89%. Axis Direct maintains a buy rating on the stock due to its strong earnings and expansion plans.

Aurobindo Pharma Commissions Four Manufacturing Facilities - 02 Apr, 2024

Aurobindo Pharma has commissioned four cutting-edge manufacturing facilities for Penicillin-G, 6-Amino Penicillanic Acid (6-APA), Injectable products, and Granulation. The Penicillin-G facility in Andhra Pradesh has a capacity of 15,000 tonne per annum and is expected to start trial production in April.

Aurobindo Pharma Commissions Four Manufacturing Facilities - 01 Apr, 2024

Aurobindo Pharma has commissioned four cutting-edge production facilities for Penicillin-G, 6-Amino Penicillanic Acid (6-APA), injectable medicines, and granulation through its wholly-owned subsidiaries. The Penicillin-G facility in Kakinada SEZ area has the ability to create 15,000 tonnes annually and was approved under the Production Linked Incentive Program. Shares rose by 4%.

Aurobindo Pharma Maintains Robust Price Structure - 29 Mar, 2024

Aurobindo Pharma's stock has displayed a clear uptrend since February 2023, with consistent higher highs and higher lows. After a healthy retracement from January 2024, the stock has found support on the 26-week exponential moving average, suggesting a mean reversion scenario.

Aurobindo Pharma Appoints New Chairman; Ranks Third in Top-Performing Stocks List - 28 Mar, 2024

Aurobindo Pharma has appointed former LIC chairperson M.R. Kumar as its new non-executive independent Chairman. The company ranks third on the list of top-performing stocks, with a 113% return in a year and gross sales of Rs 21,213 crore in FY24 Q3.

Aurobindo Pharma Accused of Donating Crores to BJP - 23 Mar, 2024

Atishi alleged that Aurobindo Pharma bought electoral bonds worth Rs 52 crore, with more than half going to the BJP. Sarath Reddy, an executive at Aurobindo Pharma, was arrested in connection with the excise policy case.

Aurobindo Pharma Receives USFDA Approval for Nasal Spray - 20 Mar, 2024

Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Mometasone Furoate Monohydrate Nasal Spray. The product will be launched in Q1FY25 and has an estimated market size of $44.5 million for the twelve months ending January 2024.

Aurobindo Pharma Receives FDA Approval for Nasal Spray - 19 Mar, 2024

Aurobindo Pharma has received final approval from the US FDA to manufacture and market mometasone furoate monohydrate nasal spray. The company reported a 90.6% YoY rise in consolidated net profit to ₹936.2 crore for Q3FY24, with revenue from operations up 14.7%. Aurobindo now has a total of 507 ANDA approvals from the US FDA. Shares closed down 2.64% at ₹990.55 on the BSE.